Rapid Acquisition of Stable Azole Resistance by Candida glabrata Isolates Obtained before the Clinical Introduction of Fluconazole
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Five azole-susceptible Candida glabrata isolates obtained before 1975 became resistant to fluconazole, itraconazole, and voriconazole within 4 days of in vitro fluconazole exposure. This cross-resistance was stable for at least 4 months after removal of fluconazole and was associated with increased CgCDR1 and CgCDR2 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Self-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385 · cited 1×
“glabrata is of concern because of recent reports that up to 18% of incident bloodstream isolates are resistant to fluconazole (6, 8, 20, 21).”
BackgroundSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · cited 2×
“Multiple mechanisms of resistance have been reported, including increased expression of the ABC transporter genes CgCDR1 and CgCDR2 (PDH1), which result in decreased accumulation of intracellular fluconazole (2, 11, 17, 23), and increased expression of the CgERG11 gene encoding the fluconazole target, 14 -lanosterol d…”
BackgroundMechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis
Bennett, J. E., Izumikawa, K., & Marr, K. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1773-1777.2004 · Cited by 217 · cited 4×
“glabrata isolates upon fluconazole exposure (2, 9, 15, 22), including some for which the previous fluconazole exposure history was unknown.”
BackgroundInfluentialUpregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216 · cited 2×
“glabrata isolates upon fluconazole exposure (2, 9, 15, 22), including some for which the previous fluconazole exposure history was unknown.”
BackgroundResultMolecular biological characterization of an azole-resistant Candida glabrata isolate
Marichal, P., Vanden Bossche, H., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V, Van Broeckhoven, C., Fay, S., & Mose-Larsen, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2229 · Cited by 210
Self-citationEvolution of Drug Resistance in Experimental Populations of Candida albicans
Cowen, L. E., Sanglard, D., Calabrese, D., Sirjusingh, C., Anderson, J. B., & Kohn, L. M. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.6.1515-1522.2000 · Cited by 207
Kaur, R., Castaño, I., & Cormack, B. P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1600-1613.2004 · Cited by 167 · cited 1×
“(13) recently demonstrated that petites might be able to”
Background
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“Despite the potential for ERG11 point mutations to have a greater impact in haploid organisms (e.g., Candida glabrata) than in diploids (e.g., C. albicans), increased drug efflux is the most common resistance mechanism in C. glabrata as well (Borst et al. 2005; Sanguinetti et al. 2005).”
BackgroundEfflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Regulation of multidrug resistance in pathogenic fungi
Morschhäuser, J. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.08.002 · Cited by 300
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 295
Schwarzmüller, T., Ma, B., Hiller, E., Istel, F., Tscherner, M., Brunke, S., Ames, L., Firon, A., Green, B., Cabral, V., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004211 · Cited by 191
“glabrata utilizes a limited set of mechanisms to mount azole resistance, with ABC transporter-mediated efflux by Cdr1 and Pdh1 being the most important one, both in vitro and in vivo [32,67,99–102].”
BackgroundPfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
“The mechanistic basis for such cross-resistance has been clearly demonstrated in a number of studies and most often involves the upregulation of genes encoding the ATP-binding cassette efflux transporters, the so-called Candida drug resistance (CDR) pumps (Borst et al., 2005; MacCallum et al., 2010; Sanguinetti et al.…”
BackgroundContribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., & Sanglard, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017589 · Cited by 110
“albicans [7,8].”
Espinel-Ingroff, A., Pfaller, M. A., Bustamante, B., Canton, E., Fothergill, A., Fuller, J., Gonzalez, G. M., Lass-Flörl, C., Lockhart, S. R., Martin-Mazuelos, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-13 · Cited by 105
Aneuploidy Enables Cross-Adaptation to Unrelated Drugs
Yang, F., Teoh, F., Tan, A. S. M., Cao, Y., Pavelka, N., & Berman, J. (2019) · Molecular Biology and Evolution · doi:10.1093/molbev/msz104 · Cited by 101
Shin, J. H., Chae, M. J., Song, J. W., Jung, S.-I., Cho, D., Kee, S. J., Kim, S. H., Shin, M. G., Suh, S. P., & Ryang, D. W. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00381-07 · Cited by 86
Antifungal drug resistance in Candida species
Morace, G., Perdoni, F., & Borghi, E. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.09.002 · Cited by 80
“[5,7–10,12,32–47,53–60].”
BackgroundOrta‐Zavalza, E., Guerrero‐Serrano, G., Gutiérrez‐Escobedo, G., Cañas‐Villamar, I., Juárez‐Cepeda, J., Castaño, I., & De Las Peñas, A. (2013) · Molecular Microbiology · doi:10.1111/mmi.12247 · Cited by 61
“…decreased susceptibility in the absence of HST1 The overexpression of ABC efflux pumps represents the major mechanism responsible for high-level azole resistance in C. glabrata isolates (Bennett et al., 2004; Brun et al., 2004; Borst et al., 2005; Cannon et al., 2009; Ferrari et al., 2009).”
BackgroundGamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642358 · Cited by 58
“glabrata which occur as a result of CgPDR1 GOF mutation (Ghannoum and Rice, 1999; Borst et al., 2005; Vale-Silva et al., 2013; Sanglard and Coste, 2016).”
BackgroundTumbarello, M., Sanguinetti, M., Trecarichi, E. M., La Sorda, M., Rossi, M., de Carolis, E., de Gaetano Donati, K., Fadda, G., Cauda, R., & Posteraro, B. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn381 · Cited by 53
Salazar, S. B., Wang, C., Münsterkötter, M., Okamoto, M., Takahashi-Nakaguchi, A., Chibana, H., Lopes, M. M., Güldener, U., Butler, G., & Mira, N. P. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/fox079 · Cited by 31
“The remarkably high rate at which C. glabrata strains acquire resistance to azoles, higher than the one registered for any other Candida spp, is another key factor contributing for the emergence of resistant strains (Borst et al., 2005, Pfaller et al., 2013, Kolaczkowska & Kolaczkowski, 2016).”
BackgroundAzole Resistance of Candida glabrata in a Case of Recurrent Fungemia
Posteraro, B., Tumbarello, M., La Sorda, M., Spanu, T., Trecarichi, E. M., De Bernardis, F., Scoppettuolo, G., Sanguinetti, M., & Fadda, G. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00526-06 · Cited by 30
“glabrata clinical isolates (2, 11, 13) and in vitro (3).”
BackgroundUsher, J., & Haynes, K. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008259 · Cited by 27
“glabrata isolates, and thus are often resistant to FLZ therapy [20,21].”
BackgroundKsiezopolska, E., Schikora-Tamarit, M. À., Carlos Nunez-Rodriguez, J., & Gabaldón, T. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1416509 · Cited by 15
Hatwig, C., Balbueno, E. A., Bergamo, V. Z., Pippi, B., Fuentefria, A. M., & Silveira, G. P. (2019) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902019000218025 · Cited by 6
Metadata
- Authors
- Borst, A., Raimer, M. T., Warnock, D. W., Morrison, C. J., & Arthington-Skaggs, B. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2005-02
- Volume
- 49
- Issue
- 2
- Pages
- 783-787
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2075439470
- Cited by
- 106
- References
- 15
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.